Photo

Photo detail

Crinetics Pharmaceuticals recently raised $102 million through an initial public offering. Standing right to left in Crinetics’ lab space that’s under construction: CEO Scott Struthers; chief financial officer Marc Wilson; and Steve Betz, a co-founder and vice president of biology.

Stories this photo appears in:

IPO Puts Crinetics In Position to Compete

BIOTECH: Oral Drug Replaces Shot, Aims for Greater Efficacy

After early years operating on a shoestring budget, Crinetics Pharmaceuticals is flush with cash to pursue ambitious drug development plans.

Tease photo